Cargando…

Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model

Pancreatic ductal adenocarcinoma (PDAC) is a particularly deadly disease. Chronic conditions, including obesity and type-2 diabetes are risk factors, thus making PDAC amenable to preventive strategies. We aimed to characterize the chemo-preventive effects of metformin, a widely used anti-diabetic dr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Hui-Hua, Moro, Aune, Chou, Caroline Ei Ne, Dawson, David W., French, Samuel, Schmidt, Andrea I., Sinnett-Smith, James, Hao, Fang, Hines, O. Joe, Eibl, Guido, Rozengurt, Enrique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897574/ https://www.ncbi.nlm.nih.gov/pubmed/29651002 http://dx.doi.org/10.1038/s41598-018-24337-8

Ejemplares similares

Deficiency in hormone-sensitive lipase accelerates the development of pancreatic cancer in conditional KrasG12D mice
por: Xu, Mu, et al.
Publicado: (2018)

Low dosage combination treatment with metformin and simvastatin inhibits obesity-promoted pancreatic cancer development in male KrasG12D mice
por: Teper, Yaroslav, et al.
Publicado: (2023)

Incidence of pancreatic cancer is dramatically increased by a high fat, high calorie diet in KrasG12D mice
por: Chang, Hui-Hua, et al.
Publicado: (2017)

Statins Inhibit Inflammatory Cytokine Production by Macrophages and Acinar-to-Ductal Metaplasia of Pancreatic Cells
por: Ako, Soichiro, et al.
Publicado: (2022)

Lipophilic statins inhibit YAP nuclear localization, co-activator activity and colony formation in pancreatic cancer cells and prevent the initial stages of pancreatic ductal adenocarcinoma in Kras(G12D) mice
por: Hao, Fang, et al.
Publicado: (2019)

Crosstalk between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance
por: Rozengurt, Enrique, et al.
Publicado: (2021)

Yes-associated protein (YAP) in pancreatic cancer: at the epicenter of a targetable signaling network associated with patient survival
por: Rozengurt, Enrique, et al.
Publicado: (2018)

Role and regulation of Yap in KrasG12D-induced lung cancer
por: Mao, Yaopan, et al.
Publicado: (2017)

Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors
por: Goebel, Lisa, et al.
Publicado: (2023)

Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells
por: Ming, Ming, et al.
Publicado: (2014)

KRasG12C inhibitors in clinical trials: a short historical perspective
por: Goebel, Lisa, et al.
Publicado: (2020)

Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development
por: Rozengurt, Enrique, et al.
Publicado: (2019)

Obesity and Pancreatic Cancer: Insight into Mechanisms
por: Eibl, Guido, et al.
Publicado: (2021)

Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells: Implications for Targeted Therapy
por: Sinnett-Smith, James, et al.
Publicado: (2022)

Addition of metabolomics to the omics spectrum for cancer biomarker development– demonstration with the KrasG12D mouse model for pancreatic carcinoma
por: Laiakis, Evagelia C, et al.
Publicado: (2014)

Different Patterns of Akt and ERK Feedback Activation in Response to Rapamycin, Active-Site mTOR Inhibitors and Metformin in Pancreatic Cancer Cells
por: Soares, Heloisa P., et al.
Publicado: (2013)

Molecular and Functional Characteristics of Ovarian Surface Epithelial Cells Transformed by KrasG12D and loss of Pten in a Mouse Model in vivo
por: Mullany, Lisa K., et al.
Publicado: (2011)

KRAS-related noncoding RNAs in pancreatic ductal adenocarcinoma
por: Yu, Shuang-Ni, et al.
Publicado: (2016)

Obesity-Induced Adipose Tissue Inflammation as a Strong Promotional Factor for Pancreatic Ductal Adenocarcinoma
por: Chang, Hui-Hua, et al.
Publicado: (2019)

HMGA1 expression levels are elevated in pancreatic intraepithelial neoplasia cells in the Ptf1a-Cre; LSL-KrasG12D transgenic mouse model of pancreatic cancer
por: Veite-Schmahl, Michelle J, et al.
Publicado: (2017)

PKD1 Mediates Negative Feedback of PI3K/Akt Activation in Response to G Protein-Coupled Receptors
por: Ni, Yang, et al.
Publicado: (2013)

Correction: PKD1 Mediates Negative Feedback of PI3K/Akt Activation in Response to G Protein-Coupled Receptors
por: Ni, Yang, et al.
Publicado: (2014)

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy
por: Gurreri, Enrico, et al.
Publicado: (2023)

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
por: Macaya, Irati, et al.
Publicado: (2023)

Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma
por: Liu, Yu-Huei, et al.
Publicado: (2022)

KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
por: Zhang, Zining, et al.
Publicado: (2023)

Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2023)

Mass spectrometry quantifies target engagement for a KRASG12C inhibitor in FFPE tumor tissue
por: Chambers, Andrew G., et al.
Publicado: (2023)

NMR-based metabolic profiling of urine, serum, fecal, and pancreatic tissue samples from the Ptf1a-Cre; LSL-KrasG12D transgenic mouse model of pancreatic cancer
por: Schmahl, Michelle J., et al.
Publicado: (2018)

Notch1 Is Not Required for Acinar-to-Ductal Metaplasia in a Model of Kras-Induced Pancreatic Ductal Adenocarcinoma
por: Avila, Jacqueline L., et al.
Publicado: (2012)

EPHA2-dependent outcompetition of KRASG12D mutant cells by wild-type neighbors in the adult pancreas
por: Hill, William, et al.
Publicado: (2021)

TNF-α and LPA promote synergistic expression of COX-2 in human colonic myofibroblasts: role of LPA-mediated transactivation of upregulated EGFR
por: Yoo, James, et al.
Publicado: (2013)

KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
por: Luchini, Claudio, et al.
Publicado: (2020)

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
por: Ashok Kumar, Prashanth, et al.
Publicado: (2023)

Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma
por: Yousef, Abdelrahman, et al.
Publicado: (2023)

Differential expression of RBM5 and KRAS in pancreatic ductal adenocarcinoma and their association with clinicopathological features
por: PENG, JIE, et al.
Publicado: (2013)

Differential Effects of Dietary Macronutrients on the Development of Oncogenic KRAS-Mediated Pancreatic Ductal Adenocarcinoma
por: Zhu, Liang, et al.
Publicado: (2022)

Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype
por: Fu, Yong, et al.
Publicado: (2015)

Disruption of p16 and Activation of Kras in Pancreas Increase Ductal Adenocarcinoma Formation and Metastasis in vivo
por: Qiu, Wanglong, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_61mb3csdqsdjav9n32krl0npk1